Two Experimental Ebola Vaccines Set for Phase 2 Trials in DRC as Scientists Intensify Fight Against Deadly Virus
The global fight against Ebola is entering a new phase as scientists prepare to advance two experimental vaccines into Phase 2 clinical trials in the Democratic Republic of Congo (DRC), raising hopes for improved protection against one of the world’s most dangerous infectious diseases.
The development marks an important step in ongoing efforts to strengthen Ebola prevention, particularly in regions that have experienced repeated outbreaks and continue to face challenges associated with limited healthcare resources, poor infrastructure and the rapid spread of infectious diseases.
The planned trials will assess the safety and effectiveness of the two experimental vaccines, providing researchers with additional information about their potential to protect people against Ebola. The research is also expected to contribute to the broader global effort to develop more effective vaccines that can be deployed quickly when outbreaks occur.
The Democratic Republic of Congo has been at the centre of numerous Ebola outbreaks over the years, making it an important location for vaccine research and clinical trials. Scientists and public health officials have continued to explore ways of improving prevention, diagnosis, treatment and response strategies to reduce the devastating impact of the virus.
Understanding the Bundibugyo strain of Ebola
The two experimental vaccines are specifically designed to target the Bundibugyo virus, a species of Ebola that has caused serious outbreaks in parts of Africa.
Ebola is a highly infectious disease that can cause severe illness, including fever, weakness, vomiting, diarrhoea, internal and external bleeding in some patients, and organ failure. The virus can spread through direct contact with the bodily fluids of an infected person or someone who has died from the disease.
Although several Ebola vaccines have been developed over the years, existing vaccines have primarily targeted the Zaire ebolavirus species. The Bundibugyo virus is genetically different, meaning vaccines developed against other Ebola species may not provide sufficient protection.
This distinction has become particularly important in the Democratic Republic of Congo, where the current outbreak has been driven by the Bundibugyo virus.
Scientists have therefore been working to develop vaccines that specifically target this strain, hoping to close a significant gap in global Ebola prevention.
The two candidates entering the next phase of testing represent an important development because they have been designed specifically to generate immune responses against the Bundibugyo virus.
The research could potentially provide a new tool for protecting people living in areas where outbreaks occur and for preventing the disease from spreading to other communities and countries.
The current outbreak has also highlighted the importance of investing in research into different Ebola species rather than concentrating exclusively on the strains that have previously received the greatest attention.
The two vaccine candidates and how they work
The two vaccines expected to enter Phase 2 testing are ChAdOx1 BDBV and mRNA-1469. They were developed by different scientific teams and use different technologies to stimulate the body’s immune system.
Developed by the University of Oxford in partnership with the Serum Institute of India, this vaccine uses a modified adenovirus to deliver genetic instructions that help the body recognise the Bundibugyo virus and develop an immune response.
Developed by Moderna, this vaccine uses messenger RNA technology to instruct cells to produce a viral protein that can stimulate the immune system to recognise and fight the Bundibugyo virus.
Both vaccines aim to train the immune system to recognise the virus before a person becomes infected. By stimulating the production of immune responses, researchers hope vaccinated individuals will be better protected against the disease if they are exposed to the virus.
The vaccines have shown encouraging results in earlier research, including studies that assessed their ability to stimulate immune responses. However, further testing is necessary to establish their safety and determine whether they can provide meaningful protection against infection and severe illness.
The Phase 2 trials will therefore be an important opportunity for scientists to collect additional evidence and determine whether the vaccines are suitable for further development.
What Phase 2 trials will establish
The next stage of research will focus on evaluating the safety of the vaccines and their ability to stimulate the body’s immune system.
During clinical trials, researchers closely monitor participants for possible side effects, reactions and other health complications associated with vaccination.
They also measure immune responses to determine whether the vaccines are capable of producing the biological reactions necessary to protect against the virus.
Phase 2 testing is an important step in vaccine development because it provides more information about how a vaccine behaves in humans and helps scientists determine whether it should advance to larger studies.
If the candidates demonstrate promising safety profiles and immune responses, they could proceed to Phase 3 trials, where researchers would evaluate their effectiveness on a larger scale.
Phase 3 studies are generally designed to establish whether a vaccine provides sufficient protection against the disease, while gathering additional safety information from a larger population.
The researchers will need to demonstrate that the vaccines offer meaningful protection before health authorities can consider approving them for widespread use.
This means that although the announcement represents significant progress, the vaccines are still experimental and are not yet available for general vaccination.
The research is being conducted under the Tumaini trial, a platform designed to evaluate multiple vaccine candidates against Bundibugyo virus disease within a single clinical research programme.
The trial is expected to expand as additional vaccine candidates become available, allowing scientists to compare different approaches and identify the most promising options.
Anadolu Agency+1
The Tumaini trial and the ring vaccination strategy
The two experimental vaccines will be evaluated through the Tumaini clinical trial, a research initiative launched in the DRC to investigate vaccine candidates against Bundibugyo Ebola.
Tumaini, a Swahili word meaning “hope,” reflects the expectations surrounding the research and the possibility of developing better protection against the deadly virus.
The trial uses a ring vaccination strategy, which involves identifying people who have been in contact with confirmed Ebola patients and offering vaccination to individuals within those contact networks.
This approach allows researchers to focus on people who are at a higher risk of exposure while closely monitoring the effectiveness of the vaccines.
The strategy was previously used during the West African Ebola outbreak, where research helped establish the effectiveness of the Ervebo vaccine against the Zaire strain of Ebola.
In the current trial, researchers are also evaluating Ervebo to determine whether it provides protection against the Bundibugyo virus, despite being developed specifically for a different Ebola species.
The inclusion of multiple vaccine candidates in one research programme allows scientists to compare different approaches while responding to the urgency of the outbreak.
The trial is being conducted in collaboration with the DRC’s National Institute of Biomedical Research, the University of Antwerp, the World Health Organization, Médecins Sans Frontières, Epicentre and other international research partners.
The Coalition for Epidemic Preparedness Innovations has also supported the development and advancement of the vaccine candidates.
The collaboration highlights the importance of international partnerships in responding to outbreaks that require scientific expertise, funding, medical infrastructure and coordination across different countries.
DRC’s ongoing Ebola crisis
The advancement of the two vaccines comes as the Democratic Republic of Congo continues to battle a major Ebola outbreak that has placed significant pressure on its healthcare system.
The country has experienced several Ebola outbreaks over the years, with communities in remote areas often facing difficulties accessing medical services and receiving timely treatment.
The current outbreak, caused by the Bundibugyo virus, has been particularly concerning because of its scale and the high number of reported deaths.
According to figures reported by the World Health Organization in November 2026, the outbreak had surpassed 11,300 cases and 5,500 deaths, while hundreds of new infections were still being reported weekly.
The outbreak has also exposed the challenges of responding to infectious diseases in areas affected by insecurity, limited healthcare infrastructure and difficulties accessing affected communities.
Health workers have faced challenges in identifying infections, tracing contacts, transporting patients and providing treatment to those who require urgent medical attention.
Attacks against health workers and healthcare facilities have also complicated response efforts, discouraging some communities from seeking medical assistance.
The introduction of new experimental vaccines could therefore provide an additional tool for health authorities, particularly if the candidates eventually demonstrate strong protection against the virus.
However, experts have stressed that vaccines alone cannot end an Ebola outbreak. Effective containment also requires surveillance, contact tracing, infection prevention, community engagement, safe burial practices and timely treatment of infected patients.
The importance of vaccine research for Africa
The development of vaccines specifically targeting the Bundibugyo virus represents an important milestone in global health research, particularly for African countries that have repeatedly experienced outbreaks of Ebola and other infectious diseases.
For many years, vaccine research has focused on diseases with the greatest global attention and funding. However, outbreaks in Africa have demonstrated the need for scientific investments that address diseases affecting communities in regions with limited access to healthcare.
The advancement of the two experimental vaccines could contribute to changing that situation by expanding the number of tools available to health authorities.
If successful, the vaccines could potentially help protect healthcare workers, people living in outbreak-affected communities, contacts of infected patients and other individuals at high risk of exposure.
The research could also strengthen preparedness for future outbreaks by helping scientists establish how quickly vaccine candidates can be developed, tested and deployed when a new infectious disease threat emerges.
The DRC’s participation in the clinical trial is also significant because it places affected communities at the centre of the research process.
People participating in clinical trials contribute valuable information that can help scientists understand whether experimental vaccines are safe and effective. Their participation can also support the development of interventions that may benefit communities across Africa and beyond.
Nevertheless, researchers must ensure that clinical trials are conducted according to strict ethical and scientific standards, with participants receiving appropriate information, medical supervision and protection throughout the process.
A promising development, but more research is needed
The decision to advance two experimental Ebola vaccines into Phase 2 trials represents a promising development in the ongoing fight against the Bundibugyo virus.
Scientists now have an opportunity to gather additional evidence about the safety and immune responses generated by the candidates while working towards identifying vaccines capable of providing meaningful protection against the disease.
The research comes at a critical moment for the Democratic Republic of Congo, where the ongoing outbreak has claimed thousands of lives and placed enormous pressure on communities and healthcare workers.
Although the vaccines are not yet approved for widespread use, their advancement into the next stage of clinical testing offers hope that more effective prevention strategies could eventually become available.
The coming months will be important as researchers evaluate the candidates, monitor participants and determine whether either vaccine can progress to larger clinical trials.
For the communities affected by Ebola, the development represents another step towards a future in which outbreaks can be contained more effectively and fewer lives are lost to the deadly virus.
The success of the research will ultimately depend on the scientific evidence generated through the trials. However, the advancement of the two candidates demonstrates the growing commitment of international health organisations, scientists and governments to finding lasting solutions to Ebola.
As the world continues to battle infectious diseases, the research in the DRC could become an important contribution to global vaccine development and epidemic preparedness.


